Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
Blog Article
Chunmei Cui, Hong Lu Department of Ophthalmology, Beijing Chao-Yang Hospital, Beijing, China Purpose: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of age-related macular degeneration (AMD).Although this novel drug has been widely used in clinic, trailmaster challenger 200x unlike other anti-VEGF drugs, validation and consensus on its method of clinical application and clinical safety have not yet been achieved.Methods: Relevant literature was searched on PubMed, Web of Science, China National Knowledge Internet, and Wanfang Data.Stata 12.
0 was used for data analysis.Random- and fixed-effect models were employed to evaluate heterogeneity.Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were utilized to measure the improvement of AMD patients.Results: In this study, we analyzed conbercept administration and compared its application with other control clinical methods for AMD treatment.
Ranibizumab, triamcinolone, and traditional transpupillary thermotherapy (TTT) g5210t-p90 were administered in the control group.No differences were found in the BCVA and CRT improvement between the groups treated with conbercept and ranibizumab.However, the conbercept group had a lower serum VEGF level.After 3 months of treatment, conbercept led to a more significant BCVA and CRT improvement than triamcinolone.
A more considerable BCVA improvement was observed in the group treated with conbercept than in the group treated with TTT.Moreover, even 6 months after the treatment, the effect of conbercept on CRT improvement was still more pronounced than that of TTT.Conclusion: In AMD patients, conbercept exerts considerably more positive effects on the long-term BCVA and CRT improvement than triamcinolone and TTT.The serum VEGF level in the conbercept group was lower than that in the ranibizumab group.
Keywords: AMD, VEGF, conbercept, BCVA, CRT.